Casdin Partners GP, LLC 4

What Happened

• Casdin Capital, LLC — identified as a 10% owner of GeneDx (ticker: WGS) — reported two open-market purchases totaling 200,000 shares. On 2026-06-04 it acquired 150,000 shares at $56.44 each ($8,466,735) and on 2026-06-05 it acquired 50,000 shares at $52.86 each ($2,642,830), for a combined outlay of approximately $11.11 million. These were outright purchases (code P), which are generally viewed as a purchase/bullish signal rather than a sale.

Key Details

• Transaction dates & prices:
  • 2026-06-04: 150,000 shares @ $56.44 — $8,466,735
  • 2026-06-05: 50,000 shares @ $52.86 — $2,642,830
• Total shares purchased: 200,000; total value: ≈ $11.11M.
• Shares owned after transaction: not specified in the provided filing details.
• Notable footnotes:
  • F1 indicates those securities are directly owned by Casdin Partners Master Fund, L.P. and may be indirectly beneficially owned by Casdin Capital, the GP, and Eli Casdin.
  • F2–F4 show related holdings directly held by Eli Casdin, the GP, and CMLS Holdings; Eli Casdin is noted in governance roles that share voting/investment discretion.
  • Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing timeliness: Form filed 2026-06-08 covering trades on 2026-06-04 and 2026-06-05. The filing does not indicate a late-report flag in the provided data; investors can verify the SEC filing timestamp for timeliness.

Context

• These purchases were reported by a 10% owner / investment-adviser-related entity (institutional/insider group), not necessarily an operating executive. Purchases by large shareholders can indicate added exposure by the fund or related parties but do not by themselves reveal motive.
• No options exercises, awards, gifts, or tax-withholding transactions were reported in these entries — only open-market purchases.